Summary Report of Consolidated Financial Results
For the Three Months Period ended June 30, 2011
August 10, 2011stCompany name: NIPRO CORPORATION
TSE/OSE-1 section
Code No.8086
URL: http://www.nipro.co.jp/
Representative: Minoru Sano, President and Representative Director
Contact person: Akihiko Yamabe, Director and General Manager of Accounting Division
TEL: (06)6372-2331
Filling date of quarterly reporting: August 12, 2011
Payment date of cash dividends: Supplemental material on quarterly reporting: No
Presentation on quarterly results: No(Note: Amounts are truncated to one million yen)
1. Consolidated Results for the Three Months ended June 30, 2011 (From April 1, 2011 to June 30, 2011)(1) Consolidated Results of Operations(Note: % of change from the same period a year ago)
Net Sales
Operating Income
Ordinary Income
Net Income
Millions of yen% Millions of yen% Millions of yen% Millions of yen%
3 months ended June 30, 201149,1559.1
3,458(27.5)
2,539
(1.1)
292
(78.3)
3 months ended June 30, 2010
45,061
3.3
4,772
17.7
2,566
(17.8)
1,348
2.0
Note: Comprehensive income

3 months ended June 30, 2011: (3,563) million yen (-%)

3 months ended June 30, 2011
3 months ended June 30, 2010

Earnings per share
Yen
4.61
21.27

(2) Consolidated Financial Position
Total Assets
Millions of yen
3 months ended June 30, 2011
490,331
Year ended March 31, 2011
476,510
Note: Equity

2.

3 months ended June 30, 2010: 30 million yen (-%)

Diluted Earnings per share
Yen
4.04
19.19

Net Assets
Millions of yen
104,019
109,037

3 months ended June 30, 2011: 100,660 million yen

Equity Ratio
%
20.5
22.4

Year ended March 31, 2011: 106,509 million yen

Dividends

Year ended March 31, 2011
Year ending March 31, 2012
Year ending March 31, 2012
(Forecast)First-quarter
Yen-

Annual Dividends per Year
Year-end Dividends
Second-quarter
Third-quarter
Yen
Yen
Yen
18.50
31.50
24.00

-

29.00

Annual Dividends

Yen
50.00
53.00

Note: Revisions to the forecast of cash dividends in the current quarter: No
3. Forecast of Consolidated Financial Results for the Year ending March 31, 2012 (From April 1, 2011 to March 31, 2012)(Note: The % displays in the line of six months ending Sept. 30, 2011 show increase/decrease ratio against the six months
ended Sept. 30, 2010. The % displays in the line of year ending March 31, 2012 show increase/decrease ratio against theyear ended March 31, 2011)
OperatingEarnings
Net Sales
Ordinary Income
Net Income
Incomeper Share
Millions of yen%
Millions of yen%
Millions of yen%
Millions of yen%
Yen
6 months ending Sept. 30, 2011
100,000 5.7
6,600 (26.9)
4,300 (21.4)
1,150(53.4)
18.13
Year ending March 31, 2012
213,000
8.7
16,450(4.5)
13,400
0.2
5,850
138.2
92.24
Note: Revisions to the forecast of consolidated financial results in the current quarter: No

4. Others(1) Change in Significant Subsidiaries during the Current Period(Change in specified subsidiaries caused a change in the scope of consolidation): Yes
Additional: 2 (Corporate name: Nipro India Corporation Pvt Ltd.)
Removal: 0(Corporate name: Nipro Medical (Hefei) Co., Ltd.)(2) Adoption of Accounting Treatments Simplified or Unique for Preparation: No(3) Change in Accounting Policies and Accounting Estimate and Restatement[1] Changes in accounting policies by a newly issued accounting pronouncement[2] Changes other than [1][3] Change in accounting estimate[4] Restatement

: No
: No
: No
: No

(4) Issued Shares (Common stock)[1] Number of issued shares at end of the period (including treasury stock):
3 months ended June 30, 2011: 63,878,505 sharesYear ended March 31, 2011: 63,878,505 shares[2] Number of treasury stock at end of the period:
3 months ended June 30, 2011: 456,554 sharesYear ended March 31, 2011: 456,420 shares[3] Average number of shares during the period:
3 months ended June 30, 2011: 63,422,023 shares
3 months ended June 30, 2010: 63,423,116shares*Information regarding the quarterly review procedure
This quarterly summary report is exempt from quarterly review procedure based on the Financial Instruments
and Exchanges Act. It is under the review procedure process at the time of disclosure of this report*Disclaimer regarding projection information including appropriate use of forecasted financial result, and otherspecial notes
The projection figures shown above are based on information that was available at the time of preparation and may
contain certain uncertainties. Actual performance and other factors may differ from these projections due tochanges in circumstances and other developments. More information concerning these forecasts can be found in P.3“1. Qualitative information for the three months period ended June 30, 2011, (3) Qualitative information concerning
forecast of consolidated financial results” in the attachment.

Table of Contents

1.

2.

3.

Qualitative Information for the Three Months Period ended June 30, 20112(1) Qualitative Information Concerning Consolidated Financial Results2(2) Qualitative Information on the Consolidated Financial Position

3(3) Qualitative Information Concerning Forecast of Consolidated Financial Results3

Summary (Other) Information

3(1) Overview of Changes in Significant Consolidated Subsidiaries

3(2) Overview of Accounting Treatments Simplified or Unique for Preparation

3(3) Overview of Changes in Accounting Principles, Procedures and Disclosure for Preparation

3(4) Additional Information

3

Consolidated Financial Statements

4(1) Quarterly Consolidated Balance Sheets

4(2) Quarterly Consolidated Statements of Income andQuarterly Consolidated Statements of Comprehensive Income

6

Quarterly Consolidated Statements of Income

6

Quarterly Consolidated Statements of Comprehensive Income

6(3) Notes Related to Going Concern

7(4) Segment Information

7(5) Notes to Statements of Shareholders‟ Equity, If Having Significant Variation

8(6) Material Subsequent Event

9

-1-

1.

Qualitative Information for the Three Months Period ended June 30, 2011

(1) Qualitative Information Concerning Consolidated Financial Results
During the current quarter period ended June 30, 2011, the world economy slowed down due to delayed economic
recovery in America and financial crisis in Europe especially in Greece.
As for the domestic economy, on the other hand, there is a great uncertainty because of the lagged recovery from theGreat East Japan Earthquake and the stagnation of companies‟ productive activities.
Under such situations, the Nipro Group got damaged when the earthquake happened to cease production insome direct offices and plants, but now they almost recover their proper functions except Kagamiishi plantof Tohoku Nipro Pharmaceutical Corporation, and we have worked hard for expansion of production andsales.
As a result, the consolidated sales in the first three months of fiscal year 2011 increased 9.1% from thesame period of the previous year to 49,155 million yen.
As for the profit, consolidated operating income decreased 27.5% from the same period of the previous
year to 3,458 million yen due to the increase in selling, general and administrative expenses, andconsolidated ordinary income decreased 1.1% from the same period of the previous year to 2,539 million
yen. The consolidated net income decreased 78.3% to 292 million yen because extraordinary expense
increased by loss generation due to disaster (777 million yen).
The overviews of the results by segment in the current period are as follows.
[1] Medical Business
Domestic market and business conditions were seriously sever because of the lagged recovery from the Great East
Japan Earthquake and economic stagnation. Under such circumstances, sales grew greatly in dialysis-related
pharmaceutical products and dialysis-related products, and also enteral-alimentation-related products, testing-related
products and vascular-related products showed fine sales. However, the overall sales remained flat.
Overseas sales suffered great effect from the appreciation of yen against the dollar and euro, but net sales grewsteadily thanks to community-based sales. We promoted sales activities in a dialysis market, and the sales of dialyzer,
blood circuits and indwelling needles showed significant growth. Plants in India, Indonesia, Bangladesh and Hefei(China) are under construction as planned to create global production system. Moreover, we started the operation tosell the products made in overseas plants to overseas subsidiaries and overseas OEM customers directly for avoiding
the risk of exchange fluctuation and aiming to disperse and reduce the risk.
As a result, net sales of this business increased 14.4% from the same period of the previous year to 34,020 million
yen[2] Pharmaceutical BusinessThis business consist of two main divisions; one is the generic drugs division to provide low cost and highquality medical drugs, and the other is contracted manufacturing division to offer high value-added products
for customer needs.
On the sales of generic drug, under government policy for the dissemination of generic products „genericdrug share in quantity shall be expanded more than 30% until year 2012,‟ the bonus points system forgeneric drug dispensing has been implemented. Thus, while the market is in underlying expansion, we
have proactively enforced sales promotion to dispensing pharmacy and deepened the cooperation withwholesaler of drug so as to increase the sales of oral drug and drug for external use. In addition, the salesof injectable drug, our main product, have grown steadily as a result of our detailed information service
mainly to the hospitals subjected to the DPC system (Diagnostic Procedure Combination; comprehension
payment system of medical cost for acute hospitalization). For these activities, net sales of this division
increased compared with the same period of the previous year.
On the sales of contracted manufacturing business, we worked hard for realizing various fine services
such as contracted development and support for value adding other than ordinary contracted
manufacturing. During this period, a number of new products have launched, but the effect of the Great
East Japan Earthquake dropped the operation capacity in some plants, so the sales of this division fell
below the sales in the same period of the previous year.
As a result, net sales of this business decreased 3.2% from the same period of the previous year to 8,922
million yen.
[3] Material Business
The sales of material glass tube for ampoule increased from the same period of the previous year because thedecrease of the domestic demand was covered by the enforcement of the sales to foreign countries. Concerningmaterial glass tube for tube bottles, on the other hand, the domestic demand remained steadily and overseas sales was
enforced to increase the sales compared with the same period of the previous year . Furthermore, we haveadvanced the formulation of pharmaceutical glass business in India and China, and overseas sales activities havealready started. The export of glass for thermos bottles had showed the trend of recovery, and in the domestic market,
power saving campaign due to the earthquake disaster created the demand of glass thermos bottles, which raise thenet sales of this products compared with the same period of the previous year. As for the sales of glass for lighting
purpose, though it was worried that the demand of automotive bulb could decrease due to the decreased production indomestic automobile industry caused by the earthquake disaster, the sales of material glass tube for electric lamp
showed stable growth thanks to the market trend to secure members for reconstruction from the disaster. However, the-2-sales of glass for LCD backlight decreased its demand under the influence of penetration of LED products, so overall,
the sales of glass products for lighting purpose and material glass tube for bulb decreased from the same period of
the previous year.
In the field of other pharmaceutical container, the sales of rubber stopper for pharmaceutical use and container for kit
form increased steadily based on our processing technique for plastics, metal and rubber. However, the sales of bags
for antimicrobial agent and parts of pre-filled syringe decreased slightly.
As for the medical preparation and administration related device, the sales had showed good increase, and we areadvancing commercialization of products by both of self- development and joint development with pharmaceuticalcompanies so as to meet the diverse need. Furthermore, we continue to promote contract manufacturing anddevelopment cooperating with domestic and foreign pharmaceutical companies in general life cycle management ofpharmaceuticals, which includes the development of combination products, systematization for self-injection andmodification of dosage form.

As a result, net sales of this business increased 2.3% from the same period of the previous year to 6,138
million yen.
[4] Other BusinessIn the other business, the sales from real estate rental income decreased 30.1% from the same period of theprevious year to 74 million yen.

(2) Qualitative Information on the Consolidated Financial Position
Analysis concerning the conditions of assets, liabilities and net assets
Total assets increased 13,821 million yen from the end of the previous period to 490,331 million yen. Current assets
increased 29,527 million yen mainly due to the increase of 26,569 million yen in cash and cash equivalent, andnoncurrent assets decreased 15,705 million yen mainly due to the decrease of 13,615 million yen in investment
securities.
Total liabilities increased 18,839 million yen from the end of the previous period to 386,311 million yen. Current liabilities
decreased 2,727 million yen mainly due to the decrease of 3,342 million yen in notes payable-facilities, and noncurrent
liabilities increased 21,566 million yen mainly due to the increase of 23,924 million yen in long-term loans payable.
Total assets decreased 5,017 million yen from the end of the previous period to 104,019 million yen. Shareholders‟equity decreased 1,774 million yen and accumulated other comprehensive income decreased 4,074 million yen.

(3) Qualitative Information Concerning Forecast of Consolidated Financial Results
In the world economy in the future, we are concerned about delayed economic expansion in America, protracted
financial turmoil in Europe and elicitation of inflation about Chinese economy. As for the domestic economy, on the other
hand, economic recovery is expected by reparation of supply chain and recovery demand. However, it is expected thatelectric power shortage and progress of appreciating yen will bring more sever business condition.
In such situation, we will aim to improve expansion and efficiency of production and sales continuously.
At this moment, there is no revision to the forecast of consolidated financial results for the FY2011 which was publishedMay 13, 2011.

2.

Summary (Other) Information(1) Change in Significant Subsidiaries during the Current Period
Nipro India Corporation Pvt Ltd. and Nipro Medical (Hefei) Co,. Ltd. are included in the scope of consolidation fromthis current period because they become more important.
(2) Accounting procedure unique for preparation of quarterly consolidated financial statements:
N/A(3) Change in Accounting Policies and Accounting Estimate and Restatement
N/A(4) Additional Information(Application of Accounting Standard for Accounting Changes and Error Corrections)
Effective after the beginning of the first quarter of FY2011, the Company has applied the Accounting Standard for
Accounting Changes and Error Corrections (ASBJ Statement No.24, issued on December 4, 2009) and Guidance on
Accounting Standard for Accounting Changes and Error Corrections (ASBJ Statement No.24, issued on December 4,2009).

-3-

3. Consolidated Financial Statements(1) [ Quarterly Consolidated Balance Sheets](Amount: million yen)
As ofJune 30, 2011
AssetsCurrent Assets
Cash and deposits
Notes and accounts receivable-trade
Merchandise and finished goods
Work in process
Raw materials and supplies
Deferred tax assets
Other
Allowance for doubtful accounts
Total current assets
Noncurrent assets
Property, plant and equipment
Bulidings and structures
Accumulated depreciation and impairment loss
Buildings and structures, net
Machinery, equipment and vehicles
Accumulated depreciation and impairment loss
Machinery equipment and vehicles, net
Land
Lease assets
Accumulated depreciation
Lease assets, net
Construction in progress
Other
Accumulated depreciation and impairment loss
Other, net
Total property, plant and equipment
Intangible assets
Goodwill
Lease assets
Other
Total intangible assets
Investments and other assets
Investment securities
Deferred tax assets
Guarantee deposits
Other
Allowance for doubtful accounts
Total investments and other assets
Total noncurrent assets
Total assets

-4-

As of
March 31, 2011

107,684
62,096
43,2107,284
11,817
3,671
11,219(435)
246,548

81,115
61,23742,697
6,783
11,461
4,204
9,935
(414)
217,021110,572(60,090)
50,481
137,956(95,401)
42,55520,287
1,604
(509)
1,095
11,082
27,466(22,599)
4,867
130,369

111,353(61,064)
50,289135,449(92,361)
43,087
20,115
1,519
(437)
1,082
8,989
27,150(22,209)
4,941
128,505

7,887
291
5,856
14,036

7,833
291
5,442
13,56891,948
2,588
415
7,377
(2,953)
99,377
243,783
490,331

105,564
2,489
3,905
8,439
(2,984)
117,414
259,488476,510(Amount: million yen)
As ofJune 30, 2011
Liabilities
Current liabilities
Notes and accounts payable-trade
Short-term loans payable
Commercial papers
Current portion of bonds
Lease obligations
Accounts payable-otherAccrued directors' bounuses
Income taxes payable
Provision for bounuses
Provision for directors' bounuses
Provision for loss on business liquidation
Provision for loss on disaster
Notes payable-facilities
Other
Total current liabilities
Noncurrent liabilities
Bonds payable
Convertible bond-type bonds
with subscription right s to shares
Long-term loans payable
Lease obligations
Deferred tax liabilities
Provision for retirement benefits
Provision for directors' retirement benefits
Provision for loss on litigation
Other
Total noncurrent liabilities
Total liabilities
Net assets
Shareholders' equity
Capital stock
Capital surplus
Retained earnings
Treasury stock
Total shareholders' equity
Accumulated other comprehensive income
Valuation difference on available-for-sale securities
Foreign currency translation adjustment
Total accumulated other comprehensive income
Minority interests
Total net assets
Total liabilities and net assets

As ofMarch 31, 2011

33,588101,175
10,000
5,000
393
5,079
1,186
1,196
61
1,954
3,750
2,594
7,693
173,674

33,581
96,65910,000
5,000
375
5,771
208
3,165
2,112
26
1,954
4,040
5,937
7,568
176,401

44,00043,00015,00015,000144,473
1,076
4,092
1,603
688
170
1,533
212,637
386,311

120,549
1,086
7,465
1,615
668
170
1,516
191,070
367,472

28,66329,97244,857(864)
102,629

28,66329,972
46,631(864)
104,403

6,139(8,107)(1,968)3,359
104,019490,331

11,387(9,281)2,106
2,527
109,037
476,510--5-

(2) [Quarterly Consolidated Statements of Income and Quarterly Consolidated Statement of Comprehensive Income]Quarterly Consolidated Statements of Income(Amount: million yen)
FY2010 first three months(From April 1, 2010
to June 30, 2010)
Net sales
Cost of sales
Gross profit
Selling, general and administrative expenses
Operating income
Non-operating income
Interest income
Dividends income
Other
Total non-operating income
Non-operating expenses
Interest expenses
Exchange loss
Equity in loss of affiliates
Other
Total non-operating expenses
Ordinary income
Extraordinary income
Gain on sales of noncurrent assets
Gain on prior period adjustment
Compensation income
Licensed dealership charges
Other
Total extraordinary income
Extraordinary loss
Loss on retirement of noncurrent assets
Abnormal manufacturing cost
Loss on adjustment for change of accounting
standard for asset retirement obligations
Loss due to disaster
Other
Total extraordinary losses
Income before income taxes and minority interests
Income taxes-current
Income taxes-deferred
Total income taxes
Income before minority interests
Minority interests in income
Net income

FY2011 first three months(From April 1, 2011
to June 30, 2011)

45,061
31,226
13,8349,062
4,772

49,15534,941
14,214
10,756
3,458

77
325
122
525

128
339
300
769

586
1,902
136
104
2,730
2,566

777
569
22
318
1,687
2,539

6
2
122
300
73
504

107
49
157

19
55

13
-

92

-

30
198
2,872
739
661
1,401
1,471
122
1,348

777
26
817
1,879
670
718
1,388
491
198
292

[Qarterly Consolidated Statements of Comprehensive Income](Amount: million yen)
FY2010 first three months(From April 1, 2010
to June 30, 2010)
Income before minority interests
Other comprehensive income
Valuation difference on available-for-sale securities
Foreign currency translation adjustment
Total other comprehensive income
Comprehensive income
Comprehensive income attributable to shareholdersof parent company
Comprehensive income attributable to minority interests-6-

FY2011 first three months(From April 1, 2011
to June 30, 2011)

1,471

491

(3,350)1,909(1,440)30(5,248)
1,193(4,054)(3,563)(97)(3,782)

128

218

(3) Notes Related to Going Concern
N/A(4) Segment InformationⅠ

FY2010 (From April 1, 2010 to June 30, 2010)

1.

Sales and Profit by Reportable Operating Segment(Millions of yen)Segment
Glass &
Materials

Other(Note.1)

Total

Consolidated
statement ofincome(Note.3)

Adjustment(Note.2)

MedicalPharmaceutical(1)Sales to third parties(2)Inter-segment sales
and transfers
Total

29,737

9,220

5,998

44,956

105

45,061-45,061

54

4,398

972

5,424

9

5,434

(5,434)-29,791

13,618

6,971

50,380115

50,496(5,434)45,061

Segment profit

5,287

724

665

6,678

21

6,700

(1,927)

4,772

Total

Net Sales(Notes)1. “Other” is the business segment which is not included in the segment and consist of real estate income and sales
by headquarter.
2. Adjustment for the segment profit of (1,927) million yen includes elimination of inter-segment transaction of 10
million yen and corporate cost of (1,937) million yen. Corporate cost consisted primarily of sales, general andadministrative expenses and research and development cost which do not belong to the reporting segment.
3. Segment profit is adjusted to the operating income on the consolidated statements of income.
2.

Information on Goodwill by Reportable Operating Segment(Significant variation in the amount of goodwill)
As for “Medical”, we included the Nipro Diagnostics, Inc. and other 3 companies in the scope of consolidation. The
regarding increase in the amount of goodwill was 12,264 million yean compared with the previous period.

-7-

Ⅱ
1.

FY2011 (From April 1, 2011 to June 30, 2011)
Sales and Profit by Reportable Operating Segment(Millions of yen)Segment
MedicalPharmaceutical

Materials

Total

Other
(Note.1)

Total

Consolidated
Statements ofIncome(Note.3)

Adjustment(Note.2)

Net sales(1)Sales to third parties

34,020

8,922

6,138

49,081

74

49,155-

49,155(2)Inter-segment sales
and transfers

336

4,324

832

5,493

11

5,504

(5,504)-

Total

34,357

13,246

6,971

54,57585

54,660(5,504)

49,155

Segment profit

3,396

1,047

605

5,049

51

5,101

(1,643)

3,458(Notes)1.
2.

3.

“Other” is the business segment which is not included in the segment and consist of real estate income and sales
by headquarter.
Adjustment for the segment profit of (1,643) million yen includes elimination of inter-segment transaction of 64
million yen and corporate cost of (1,707) million yen. Corporate cost consisted primarily of sales, general andadministrative expenses and research and development cost which do not belong to the reporting segment.
Segment profit is adjusted to the operating income on the consolidated statements of income.

2.

Change in Reportable Segment
From the current quarter period ended June 30, 2011, the name of business segment was changed partially and“Glass & Materials” is displayed as “Materials”.

3.

Information about Impairment Loss of Tangible Assets and Goodwill by Reportable Operating Segment
N/A(5) Notes to Statements of Shareholder‟s Equity, if having Significant Variation
N/A

-8-

(6) Material Subsequent Event
Acquisition of Glass Business of Amcor
1.

Content and Purpose
In July, 2011, the Nipro Group acquired the U.S. glass business from Amcor, a manufacturer dealing in packing
materials in Australia. We acquired the shares of their subsidiaries in France and Belgium as well.
Since its foundation in 1954, the Group has run material business such as glass tube for ampoules or tablet
bottles and we have promoted to expand medical and pharmaceutical businesses based on the techniquecultivated through the material business. For our long-range planning to realize 500 billion yen in consolidated net
sales by 2020, we enforce the base of the material business to reach the scale of operation to 100 billion yen.
Amcor has been engaged in pharmaceutical glass business for about 120 year. They have already establisheda lot of business relations with Western major pharmaceutical companies with the technique for producing
high-quality products. As we take over this business, we can explode our business to West countries enforcing therelations with existing business partners, and we can also develop the sales in Asia and South and Central
America using our sales network created through medical business. Furthermore, we can enjoy technical support
for glass processing business in Asia and South and Central America, which will become an important base torealize 100 billion yen in net sales of this business. From these advantages, we have decided to take over thebusiness of Amcor.

2.

Names of the Counterparty that divested the Business and Shares to us
Business in U.S.A.:
Amcor Pharmaceutical Packing USA Inc.
Subsidiary in France:
Amcor France SAS
Subsidiary in Belgium:
Amcor Investments Pty. Ltd., Amcor Holdings (Australia) Pty. Ltd.

3.

Overview of the Acquired U.S. Business(1) Business description: manufacturing and sales of glass products such as ampoule, vial and glass tube
(2) Assets and liabilities which we take overWe take over the assets and liabilities which Amcor Pharmaceutical Packing USA Inc. uses for the glassbusiness. As of the end of June, 2011, the book value of the assets is 55 million U.S. dollar and the book valueof the liabilities is 9 million U.S. dollar. We found a subsidiary in America to obtain these assets and liabilities.
(3) Overview of the subsidiary in America
Name:
Nipro Glass Americas Corporation
Capital amount:
65 million U.S. dollar
Date of foundation:
July, 2011
Ownership ratio:
Nipro Corporation 100%

4.

Overview of the Acquired Subsidiaries in France and Belgium
Subsidiary in France(1) Name:
Amcor Packing Glass Pharma SAS(2) Business description
manufacturing and sales of glass products for pharmaceutical purpose
such as ampoule, vial and glass tube
(3) Sales result:
38,670 thousand euro (Year ended June 30, 2011)
Subsidiary in Belgium(1) Name:
Amcor Verrerie Amiable Industries et Commerce SA(2) Business description:
manufacturing and sales of glass products for pharmaceutical purpose
such as pharmaceutical vials(3) Sales result:
5,310 thousand euro (Year ended June 30, 2011)5.

Date of Acquisition of the Business and Shares
July, 2011

6.

The Number of Shares, Acquisition Price and Ownership Ratio
Amcor Packing Glass Pharma SAS
The number of acquired shares
3,800,000 shares
Ownership ratio after acquisition
100%
Amcor Verrerie Amiable Industries et Commerce SA
The number of acquired shares
122,970 shares
Ownership ratio after acquisition
100%
Amount of acquisition price including American business assets is 160,920 thousand U.S. dollar.

-9-